Persistence of the Immune Response After MenACWY-CRM Vaccination and Response to a Booster Dose, in Adolescents, Children and Infants

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2016 Feb 3

PMID 26829877

Citations 13

Authors

Roger Baxter

Pavitra Keshavan

Jo Anne Welsch

Linda Han

Igor Smolenov

Affiliations

Soon will be listed here.

Abstract

Persistence of bactericidal antibodies following vaccination is extremely important for protection against invasive meningococcal disease, given the epidemiology and rapid progression of meningococcal infection. We present an analysis of antibody persistence and booster response to MenACWY-CRM, in adolescents, children and infants, from 7 clinical studies. Immunogenicity was assessed using the serum bactericidal assay with both human and rabbit complement. Post-vaccination hSBA titers were high, with an age- and serogroup-specific decline in titers up to 1 y and stable levels up to 5 y The waning of hSBA titers over time was more pronounced among infants and toddlers and the greatest for serogroup A. However, rSBA titers against serogroup A were consistently higher and showed little decline over time, suggesting that protection against this serogroup may be sustained. A single booster dose of MenACWY-CRM administered at 3 to 5 y induced a robust immune response in all age groups.

Citing Articles

From data to policy: two-dose meningococcal vaccine series are highly immunogenic.

Blatt A, Smith M Pediatr Res. 2025; .

PMID: 39962156 DOI: 10.1038/s41390-025-03940-2.

Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy.

Neri A, Fabiani M, Barbui A, Vocale C, Miglietta A, Fazio C Vaccines (Basel). 2022; 10(5).

PMID: 35632534 PMC: 9144765. DOI: 10.3390/vaccines10050778.

[ (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].

Boccalini S, Panatto D, Mennini F, Marcellusi A, Bini C, Amicizia D J Prev Med Hyg. 2021; 62(1 Suppl 1):E1-E128.

PMID: 34622076 PMC: 8452280. DOI: 10.15167/2421-4248/jpmh2021.62.1s1.

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.

Piazza F, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A Hum Vaccin Immunother. 2021; 18(1):1-10.

PMID: 34085900 PMC: 8920225. DOI: 10.1080/21645515.2021.1902701.

A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control.

Tzeng Y, Stephens D Microorganisms. 2021; 9(3).

PMID: 33802567 PMC: 7999845. DOI: 10.3390/microorganisms9030519.

References

Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N . Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun. 2003; 71(10):5549-55. PMC: 201087. DOI: 10.1128/IAI.71.10.5549-5555.2003. View

Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller J . Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2015; 12(1):132-9. PMC: 4962747. DOI: 10.1080/21645515.2015.1058457. View

Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbe M . Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2013; 383(9911):40-47. PMC: 3898950. DOI: 10.1016/S0140-6736(13)61612-8. View

Borrow R, Andrews N, Goldblatt D, Miller E . Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001; 69(3):1568-73. PMC: 98057. DOI: 10.1128/IAI.69.3.1568-1573.2001. View

Reisinger K, Baxter R, Block S, Shah J, Bedell L, Dull P . Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009; 16(12):1810-5. PMC: 2786376. DOI: 10.1128/CVI.00207-09. View

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View

Norheim G, Aase A, Caugant D, Hoiby E, Fritzsonn E, Tangen T . Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine. 2005; 23(29):3762-74. DOI: 10.1016/j.vaccine.2005.02.021. View

Christensen H, May M, Bowen L, Hickman M, Trotter C . Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12):853-61. DOI: 10.1016/S1473-3099(10)70251-6. View

Andrews N, Borrow R, Miller E . Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003; 10(5):780-6. PMC: 193909. DOI: 10.1128/cdli.10.5.780-786.2003. View

10.

Baxter R, Reisinger K, Block S, Percell S, Odrljin T, Dull P . Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014; 33(11):1169-76. DOI: 10.1097/INF.0000000000000438. View

11.

Maslanka S, Gheesling L, Libutti D, Donaldson K, Harakeh H, Dykes J . Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997; 4(2):156-67. PMC: 170495. DOI: 10.1128/cdli.4.2.156-167.1997. View

12.

Ostergaard L, Van der Wielen M, Bianco V, Miller J . Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2012; 17(3):e173-6. DOI: 10.1016/j.ijid.2012.10.001. View

13.

Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M . Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J. 2005; 24(1):57-62. DOI: 10.1097/01.inf.0000148928.10057.86. View

14.

Tregnaghi M, Lopez P, Stamboulian D, Grana G, Odrljin T, Bedell L . Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. Int J Infect Dis. 2014; 26:22-30. DOI: 10.1016/j.ijid.2014.03.1390. View

15.

Block S, Christensen S, Verma B, Xie F, Keshavan P, Dull P . Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination. Vaccine. 2015; 33(18):2175-82. DOI: 10.1016/j.vaccine.2015.02.049. View

16.

Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller J . Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012; 8(12):1892-903. PMC: 3656082. DOI: 10.4161/hv.22166. View

17.

Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M . Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006; 194(12):1745-52. DOI: 10.1086/509619. View

18.

Snape M, Kelly D, Salt P, Green S, Snowden C, Diggle L . Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006; 43(11):1387-94. DOI: 10.1086/508776. View

19.

Balmer P, Borrow R . Issues surrounding standardization of meningococcal group W135 serology. Vaccine. 2007; 25 Suppl 1:A63-8. DOI: 10.1016/j.vaccine.2007.04.043. View

20.

Klein N, Reisinger K, Johnston W, Odrljin T, Gill C, Bedell L . Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2011; 31(1):64-71. DOI: 10.1097/INF.0b013e31823dce5c. View